Targeting PD-1/PD-L1 in biliary tract cancer: role and available data
Authors
Mahmood, Reem DGraham, Kathryn
Gleeson, Jack
Hubner, Richard A
Valle, Juan W
McNamara, Mairead G
Affiliation
Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, M20 4BX, UKIssue Date
2023
Metadata
Show full item recordAbstract
There is a critical need for novel therapies to treat patients with advanced biliary tract cancer (BTC). This systematic review summarizes the evidence-based knowledge for the potential role of PD-1 and PD-L1 monoclonal antibodies in the treatment of patients with early-stage and advanced BTC. An Embase database search was conducted, identifying 15 eligible phase II/III clinical trials for review. Results from recent phase III trials show a statistically significant overall survival (OS) benefit from the addition of PD-1/PD-L1 inhibitors to chemotherapy in the first-line management of advanced BTC. Future research should concentrate on the discovery of biomarkers to identify patients who would benefit most from these therapies.Citation
Mahmood RD, Graham K, Gleeson J, Hubner RA, Valle JW, McNamara MG. Targeting PD-1/PD-L1 in biliary tract cancer: role and available data. Immunotherapy. 2023 Apr 3. PubMed PMID: 37009698. Epub 2023/04/04. eng.Journal
ImmunotherapyDOI
10.2217/imt-2022-0190PubMed ID
37009698Additional Links
https://dx.doi.org/10.2217/imt-2022-0190Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.2217/imt-2022-0190
Scopus Count
Collections
Related articles
- Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
- Authors: Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN
- Issue date: 2021 Oct
- Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis.
- Authors: Frega G, Cossio FP, Banales JM, Cardinale V, Macias RIR, Braconi C, Lamarca A
- Issue date: 2023 Aug 19
- Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.
- Authors: Zhu C, Xue J, Wang Y, Wang S, Zhang N, Wang Y, Zhang L, Yang X, Long J, Yang X, Sang X, Zhao H
- Issue date: 2023
- Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
- Authors: Kim H, Kim J, Byeon S, Jang KT, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST
- Issue date: 2021
- Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
- Authors: Shi C, Li Y, Yang C, Qiao L, Tang L, Zheng Y, Chen X, Qian Y, Yang J, Wu D, Xie F
- Issue date: 2022